- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02673762
Salivary Transcriptome Biomarkers for Early Diabetes Detection
10. april 2018 opdateret af: PeriRx
A PRoBE design study will be used to obtain saliva from patients before undergoing blood study evaluation for screening at risk patients for the presence of undiagnosed pre-diabetes of type II diabetes.
Pre-specified saliva biomarkers will be evaluated along with multi-marker models for their discriminatory value for distinguishing patients with normal glucose metabolism from those with disease.
Appropriate housekeeping genes will also be incorporated to allow for the measurement of relative gene expression.
Studieoversigt
Status
Ukendt
Betingelser
Detaljeret beskrivelse
Prospective-specimen-collection, retrospective-blinded-evaluation (PRoBE) methods will be employed to collect saliva and evaluate transcriptome markers for early pre-diabetes and type II diabetes identification.
At risk patients will have fasting blood glucose and insulin levels measured along with hemoglobin A1c and 2 hour post-prandial glucose levels.
Saliva samples will be stored and will be analyzed after pre-specifying a panel of mRNAs and a multi marker model for validation.
The pre-specified mRNAs and multi-marker model will be determined after analysis of data from a currently ongoing case-control study.
After analyzing the data from this prior trial a validation plan will be locked before analysis of the prospectively collected specimens.
Pre-diabetes will be defined based on abnormal glucose tolerance tests.
Insulin resistance will be calculated as HOMA IR.
The diagnostic value of the salivary transcriptome for will be compared with that of hemoglobin A1c and fasting blood glucose for the detection of pre-diabetes, insulin resistance and type II diabetes.
Undersøgelsestype
Observationel
Tilmelding (Forventet)
180
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Studiesteder
-
-
Texas
-
San Antonio, Texas, Forenede Stater, 78258
- San Antonio Endovascular and Heart Institute
-
-
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år og ældre (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Prøveudtagningsmetode
Ikke-sandsynlighedsprøve
Studiebefolkning
Adults with undiagnosed abnormal glucose metabolism undergoing clinically driven screening for pre-diabetes and type II diabetes.
Beskrivelse
Inclusion Criteria:
- Adult patients with unknown glucose metabolism status and
- Requiring clinically driven screening for abnormal glucose metabolism and
- Outpatient status
Exclusion Criteria:
- Patients on treatment for abnormal glucose metabolism including diet and drug therapy
- Patients with a prior diagnosis of abnormal glucose metabolism
- Patients on treatment with corticosteroids
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Kohorter og interventioner
Gruppe / kohorte |
---|
Normal glucose metabolism
Normal fasting blood glucose, 2 hour post prandial glucose, hemoglobin A1c and HOMA IR
|
Pre-diabetes
Abnormal glucose tolerance tests and/or insulin resistance with fating blood glucose and hemoglobin A1c below type II diabetes levels
|
Type II diabetes
Hemoglobin A1c 6.5% or greater, fasting blood glucose >125 mg/dl or 2 hour post-prandial blood glucose 200 mg/ml or greater
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
A multi marker test score based on a pre-specified model is measured in each patient. The test score is on a scale of 0 to 1.0 and relates to the probability of disease.
Tidsramme: At study entry
|
The area under the ROC curve is used to determine the overall performance of the model at the completion of the study.
An area over 0.7 is considered clincially significant.
|
At study entry
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Pre-specified mRNA marker Ct values from PCR analysis will be measured in individual patients
Tidsramme: At study entry
|
The performance of each individual marker will be determined at study completion my comparing median values between groups by nonparametric analysis.
A p value of less than or equal to 0.05 is considered significant.
|
At study entry
|
Housekeeping gene Ct values on PCR analysis will be measured in individual patients
Tidsramme: At study entry
|
The performance of these genes will be determined based on stability within and between groups utilizing the NormFinder program.
Stability values of < 0.2 will be considered significant.
|
At study entry
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Sponsor
Efterforskere
- Ledende efterforsker: Jack L Martin, MD, San Antonio Endovascular and Heart Institute
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart (Faktiske)
1. januar 2016
Primær færdiggørelse (Forventet)
1. december 2018
Studieafslutning (Forventet)
1. februar 2019
Datoer for studieregistrering
Først indsendt
19. december 2015
Først indsendt, der opfyldte QC-kriterier
1. februar 2016
Først opslået (Skøn)
4. februar 2016
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
12. april 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
10. april 2018
Sidst verificeret
1. april 2018
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- PeriRx003
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
INGEN
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Insulin resistens
-
Pennington Biomedical Research CenterNutrition Obesity Research CenterAfsluttetInsulinForenede Stater
-
The University of The West IndiesUkendtInsulin tjeklisteBarbados
-
Maastricht University Medical CenterNederlandse Zuivel OrganisatieAfsluttetInsulin | Glucose metabolismeHolland
-
CHU de Quebec-Universite LavalCanadian Diabetes Association; Laval University; Fonds de la Recherche en...AfsluttetD-vitaminmangel | Insulin-resistentCanada
-
Virginia Polytechnic Institute and State UniversityAfsluttetMenneskets hukommelse | Intranasal insulin
-
PepsiCo Global R&DAfsluttetBlodsukker; Subjektiv sult, insulinCanada
-
University of Alabama at BirminghamAfsluttetKnoglemineraltæthed | Fordeling af kropsfedt | Insulin homeostaseForenede Stater
-
Children's Hospital of Eastern OntarioUniversity of OttawaAfsluttetGennemførlighed | Insulin | At spise | Glukose | LipiderCanada
-
Stephanie B. Seminara, MDRekrutteringGraviditet | Sunde frivillige | Insulin | Glukose | KvinderForenede Stater
-
Transdermal Delivery Solutions CorpLangford Research Institute, Inc.AfsluttetFarmakodynamisk respons på små doser insulinForenede Stater